CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2023

Company entered into strategic collaboration with Moderna to use Generation Bio’s proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside

CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary.

Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system Moderna has acquired an option to license Generation Bio’s ctLNP

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene

— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of $279.1M provides expected runway into 2025 CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41 st Annual J.P.